查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677231

个人化细胞和基因治疗市场按治疗类型、患者类型、治疗领域和最终用户划分 - 全球预测 2025-2030

Personalized Cell & Gene Therapies Market by Therapy Type, Patient Type, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

个人化细胞和基因治疗市场预计在 2024 年达到 138.8 亿美元，2025 年达到 163.0 亿美元，到 2030 年将达到 414.9 亿美元，复合年增长率为 20.01%。

主要市场统计数据
基准年 2024 年 138.8亿美元
预计 2025 年 163亿美元
预测年份 2030 414.9亿美元
复合年增长率（%） 20.01％

在快速发展的医学领域，个人化细胞和基因治疗已成为一个变革前沿。这些创新疗法所提供的高精度水平不仅重新定义了治疗策略，也为患有各种疾病的患者带来了前所未有的希望。在本介绍中，我们将仔细说明这些最先进治疗如何透过根据个人基因和细胞特征量身定制治疗方案来改变医疗保健的未来。

生物医学领域正从一刀切的解决方案转向更细緻入微、针对病患的方法。进入个人化治疗。这是治疗方法。这种方法利用基因组学、生物技术和临床创新的进步来治疗复杂疾病，具有更高的疗效和更少的副作用。

随着产业的不断进步，新的研究、先进的生物技术平台和策略伙伴关係关係的整合将在弥合临床潜力与实用化之间的差距方面发挥关键作用。从传统治疗方法到个人化解决方案的进展不仅推动了临床突破，而且还创造了新的市场机会。以下分析深入探讨了影响这个令人兴奋的产业未来的转型动力、细分考量、区域影响、竞争格局和策略建议。

个人化医疗格局的变革

在过去的十年中，个人化细胞和基因治疗的动态发展发生了重大转变。几个关键驱动因素改变了治疗方案的开发、检验和实施方式。这些驱动因素包括高通量定序、先进的生物资讯学和基因组编辑技术的整合，这些技术共同实现了更精准的治疗性介入。

研究突破已被证明对于从常见的免疫疗法和化疗转向在分子层面的治疗性介入方法转变至关重要。细胞重编程和标靶基因修饰的革命性技术不仅提高了治疗效果，而且扩大了可治疗的病理频谱。因此，曾经被认为超出许多患者承受能力的治疗方法现在成为了可行的选择，符合个人化医疗的原则。

世界各地的研究机构正迅速采用这些创新方法，利用学术研究机构和私人公司之间日益增多的合作。此次合作完善了药物发现、临床转化和製造可扩展性的流程。监管机构也随着这些创新而不断发展，推出简化的指导方针，以加快核准并确保安全。

这些变革不仅仅是技术上的，它们还重新定义了经营模式和市场策略。相关人员越来越多地投资于整合多组学资料的平台，以优化患者选择并提高治疗精度。诊断能力的提高将使我们能够更详细地了解疾病途径，从而使製造商能够设计出特异性针对细胞异常的治疗方法。随着这些快速进步，研究和临床实践之间的二分法正在迅速模糊，从而产生一种使患者和医疗保健提供者都受益的统一方法。

此外，创业投资和私人投资的激增增强了该行业对个人化医疗长期潜力的信心。这项投资加快了创新步伐，并确保尖端的科学研究转化为切实的患者治疗效果。随着市场动态的不断发展，该行业正在经历从渐进式改进到彻底创新的根本性转变，从而重新定义医疗保健的界限。

推动市场发展的关键细分洞察

要了解个人化细胞和基因治疗市场的广度和潜力，深入了解市场区隔是关键。我们从多个维度对市场进行了全面的分析，阐明了其复杂的结构和成长驱动因素。首先，基于治疗类型的细分区分了细胞疗法和基因疗法，为评估创新和应用提供了双重框架。这种分类使相关人员能够评估与每种治疗方式相关的独特的技术进步、监管途径和临床结果。

此外，根据患者类型进行市场细分，将市场分为成人市场、老年市场和儿童市场。此分类考虑了不同年龄层和临床背景的不同治疗需求，从而可以有效地为每个群体应用量身定制的治疗方法。每种患者类别都表现出独特的生理反应和疾病特征，需要专门的治疗策略和剂型。

此外，治疗领域部分深入研究了疾病状况，重点关注循环系统、血液学、免疫学、代谢紊乱、神经病学、肿瘤学和罕见疾病。这种多方面的分析不仅说明了个人化治疗可以解决的疾病的多样性，而且还强调了突破性治疗方法最突出的特定领域。每个治疗领域都有各自的挑战和机会，这会影响投资重点和研究重点。

最后，按最终用户进行细分考虑了该技术的各种机构和组织受益者，例如生物製药公司、医院/诊所和研究机构。区分这些群体可以进行反映推动市场动态的不同目标、资源配置和策略利益的分析。这些细分参数的整合提供了一个全面的观点，这对于制定有针对性的行销策略、识别成长机会和优化资源配置至关重要。

这些细分之间的相互作用不仅使市场更加清晰，而且还有助于预测未来趋势和发现个人化治疗中尚未开发的市场。这种综合方法将使技术创新者和政策制定者能够做出明智的决策，使技术能力与患者需求相结合。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 增加对个人化细胞和基因治疗研发的投资和资金
      • 全球遗传疾病和慢性病的发生率不断上升
    • 限制因素
      • 与个性化细胞和基因治疗相关的复杂而专业的製造工艺
    • 机会
      • 开发和整合人工智慧驱动平台，增强细胞和基因治疗的个人化
      • 透过製药公司和生物技术公司之间的策略合作加强个人化医疗
    • 任务
      • 个人化细胞和基因治疗领域熟练专家短缺
  • 市场区隔分析
    • 患者类型：脊髓性肌肉萎缩症在儿科患者中的发病率不断上升，推动了对先进细胞和基因治疗的需求
    • 最终用户：专注于推进下一代治疗方法的生物製药公司
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

第六章个人化细胞与基因治疗市场（依治疗类型）

  • 细胞疗法
  • 基因治疗

7. 个人化细胞和基因治疗市场（依患者类型）

  • 成人
  • 老年人
  • 孩子们

第 8 章个性化细胞与基因治疗市场（依治疗领域）

  • 心臟病学
  • 血液学
  • 免疫学
  • 代谢紊乱
  • 神经病学
  • 肿瘤学
  • 罕见疾病

第九章个人化细胞和基因治疗市场（按最终用户划分）

  • 生物製药公司
  • 医院和诊所
  • 研究所

10. 美洲个人化细胞与基因治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太个性化细胞与基因治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲个人化细胞和基因治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Adaptimmune Limited
  • Allogene Therapeutics
  • Amgen Inc.
  • Arcellx, Inc.
  • Beam Therapeutics Inc.
  • BioCell Innovations
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Caribou Biosciences, Inc.
  • Celyad Oncology SA
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Fate Therapeutics, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Miltenyi Biomedicine GmbH
  • Novartis AG
  • Sana Biotechnology, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc
Product Code: MRR-1F6B5542A0AC

The Personalized Cell & Gene Therapies Market was valued at USD 13.88 billion in 2024 and is projected to grow to USD 16.30 billion in 2025, with a CAGR of 20.01%, reaching USD 41.49 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 13.88 billion
Estimated Year [2025] USD 16.30 billion
Forecast Year [2030] USD 41.49 billion
CAGR (%) 20.01%

In the rapidly evolving realm of medicine, personalized cell and gene therapies have emerged as a transformative frontier. The precision offered by these innovative treatments not only redefines therapeutic strategies but also offers unprecedented hope for patients across diverse medical conditions. This introduction sets the stage for a detailed exploration of how these cutting-edge therapies are steering the future of healthcare by tailoring treatments to individual genetic and cellular profiles.

The landscape of biomedicine is shifting from one-size-fits-all solutions to a more nuanced, patient-specific approach. Enter personalized therapies - interventions meticulously designed to work with an individual's own biological characteristics. This approach leverages advances in genomics, biotechnology, and clinical innovations to address complex diseases with higher efficacy and reduced side effects.

As the industry continues to advance, the integration of novel research, sophisticated biotechnology platforms, and strategic partnerships plays a critical role in bridging the gap between clinical potential and practical application. The progression from traditional treatments to personalized solutions is not only fueling clinical breakthroughs but also generating new market opportunities. The following analysis delves deeper into the transformative dynamics, segmentation insights, regional influences, competitive landscapes and strategic recommendations that collectively shape the future of this exciting sector.

Transformative Shifts in the Landscape for Personalized Therapies

Significant transformations have characterized the dynamic evolution of personalized cell and gene therapies over the past decade. Several key drivers have reformed how treatment options are developed, validated, and administered. These drivers include the integration of high-throughput sequencing, advanced bioinformatics, and genome editing technologies that collectively enable more precise therapeutic interventions.

Research breakthroughs have proven fundamental in transitioning from general immunotherapy and chemotherapy to approaches that customize therapeutic interventions at the molecular level. Revolutionary techniques in cellular reprogramming and targeted gene modifications have not only increased the efficacy of treatments but also broadened the spectrum of treatable conditions. As a result, therapies that once were considered out of reach for many patients have now become viable options, adhering to the principle of personalized medicine.

Institutions across the globe are rapidly adopting these innovative methods, capitalizing on increased collaboration between academic research facilities and private-sector companies. This collaboration has refined the processes of drug discovery, clinical translation, and manufacturing scalability. Regulatory bodies are evolving alongside these innovations, implementing streamlined guidelines that facilitate faster approvals while ensuring safety.

These transformative shifts are not merely technological; they are also redefining business models and market strategies. Stakeholders are increasingly investing in platforms that integrate multiomic data to optimize patient selection and enhance treatment precision. Enhanced diagnostic capabilities allow for a more detailed understanding of disease pathways, enabling manufacturers to design therapies that specifically target cellular anomalies. With such rapid advancements, the dichotomy between research and clinical practice is rapidly blurring, leading to a unified approach that benefits both patients and healthcare providers.

Furthermore, the surge in venture capital and private investments underscores the industry's belief in the long-term potential of personalized therapies. These financial infusions have accelerated the pace of innovation, ensuring that the cutting edge of scientific research translates into tangible patient outcomes. As market dynamics continue to evolve, the industry is witnessing a fundamental shift from incremental improvements to radical innovations that redefine healthcare boundaries.

Key Segmentation Insights Driving Market Evolution

An in-depth understanding of market segmentation is key to grasping the breadth and potential of the personalized cell and gene therapies market. The market is comprehensively analyzed along several dimensions that reveal its intricate structure and growth drivers. Initially, segmentation based on therapy type distinguishes between cell therapy and gene therapy, thus providing a dual framework for assessing innovation and application. This classification allows stakeholders to evaluate the distinct technological advancements, regulatory pathways, and clinical outcomes associated with each treatment modality.

Furthermore, segmentation based on patient type stratifies the market into adult, geriatric, and pediatric categories. This classification acknowledges the varying therapeutic needs across different age groups and clinical backgrounds, ensuring that tailored approaches can be effectively applied to each demographic. Patients in each category present unique physiological responses and disease profiles, which in turn necessitate specialized treatment strategies and dosage formulations.

In addition, the segmentation based on therapeutic area offers a detailed examination of the disease landscape by focusing on cardiology, hematology, immunology, metabolic diseases, neurology, oncology, and rare diseases. This multifaceted analysis not only illustrates the diversity of conditions that can be addressed by personalized therapies but also highlights specific areas where breakthroughs are most prominent. Each therapeutic area comes with its own set of challenges and opportunities, influencing investment priorities and research focus.

Lastly, segmentation by end user takes into account various institutional and organizational beneficiaries of this technology, including biopharmaceutical companies, hospitals and clinics, and research institutions. By distinguishing between these groups, the analysis reflects the different objectives, resource allocations, and strategic interests that drive market dynamics. The integration of these segmentation parameters provides a comprehensive perspective that is essential for formulating targeted marketing strategies, identifying growth opportunities, and optimizing resource allocation.

The interplay between these segmentation dimensions not only enhances market clarity but also aids in predicting future trends and identifying underexploited niches within the personalized therapies landscape. This integrated approach ensures that both innovators and policymakers can make informed decisions that align technological capabilities with patient needs.

Based on Therapy Type, market is studied across Cell Therapy and Gene Therapy.

Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.

Based on Therapeutic Area, market is studied across Cardiology, Hematology, Immunology, Metabolic Diseases, Neurology, Oncology, and Rare Diseases.

Based on End User, market is studied across Biopharmaceutical Companies, Hospitals & Clinics, and Research Institutions.

Key Regional Insights Illuminating Global Trends

Geographic analysis plays a pivotal role in understanding the current progress and future potential of the personalized cell and gene therapies market. Studies reveal that the evolution of these therapies is being driven by diverse market dynamics and regulatory frameworks across various global regions. In North and South America, robust investment in biotechnology research and the presence of leading academic institutions have catalyzed significant advancements. The region has demonstrated a proactive stance in regulatory approvals and clinical validations, thereby setting benchmarks that motivate similar progress in other parts of the world.

Across Europe, the Middle East and Africa, the adoption of personalized therapies is coupled with strategic government incentives and collaborative research initiatives. European nations, in particular, have established comprehensive frameworks that combine public and private investments, leading to accelerated market penetration. Middle Eastern and African regions are gradually building capacities and are poised to benefit from knowledge transfers and technological partnerships, promising a steady upward trajectory in accessing these advanced treatments.

In the Asia-Pacific, there is an observable transformation underpinned by increasing government support, favorable regulatory reforms, and burgeoning research ecosystems. The rapid growth of biotechnology start-ups and the expansion of clinical trial networks in this region have cultivated an environment that is highly conducive to innovation. The integration of advanced telemedicine and health informatics further complements these developments, ensuring that personalized therapies reach a wider, more diverse patient base.

Collectively, these regional insights underscore the importance of localized strategies that respond to unique regulatory, economic, and cultural variables. Understanding these differences is crucial for stakeholders aiming to deploy customized market strategies. These insights further illustrate how cross-border collaborations and technology exchanges can facilitate the broader adoption of personalized cell and gene therapies on a global scale, adapting to the dynamic needs of each region while supporting overall market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Within Personalized Therapies

The competitive landscape in personalized cell and gene therapies is characterized by a dynamic roster of pioneering companies working to revolutionize treatment modalities. Market leaders such as Adaptimmune Limited, Allogene Therapeutics, Amgen Inc., Arcellx, Inc., and Beam Therapeutics Inc. are at the forefront of developing innovative treatment platforms that harness the power of cellular engineering and genome editing. These companies continuously invest in cutting-edge research and clinical trials to push the boundaries of therapeutic capabilities.

Emerging innovators like BioCell Innovations and bluebird bio, Inc. have built robust pipelines that strive to address previously unreachable therapeutic areas, while established names like Bristol-Myers Squibb Company and Caribou Biosciences, Inc. are leveraging decades of experience in the pharmaceutical industry to bring personalized treatments to market. Companies such as Celyad Oncology SA and CRISPR Therapeutics AG have refined their approaches to gene editing, marking significant milestones in the effective treatment of complex diseases.

The landscape is further enriched by entities including Editas Medicine, Inc., Fate Therapeutics, Inc., Genentech, Inc., and Gilead Sciences, Inc., each contributing uniquely to the science and commercialization of personalized therapies. Intellia Therapeutics, Inc. and Lonza Group Ltd. bring state-of-the-art manufacturing innovations that are crucial in scaling up production. Miltenyi Biomedicine GmbH, Novartis AG, Sana Biotechnology, Inc., Sangamo Therapeutics, Inc., and Sarepta Therapeutics, Inc. have also been instrumental in addressing regulatory challenges and ensuring that new therapies adhere to the highest quality standards.

The continued evolution and competitive nature of this market necessitate an emphasis on collaboration and the sharing of technological advancements. These key players, with their extensive research, robust technological portfolios, and strategic foresight, collectively drive industry benchmarks and contribute to the rapid pace of market evolution. Their interplay not only stimulates healthy competition but also fuels innovation and broadens the potential for future therapeutic breakthroughs.

The report delves into recent significant developments in the Personalized Cell & Gene Therapies Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Limited, Allogene Therapeutics, Amgen Inc., Arcellx, Inc., Beam Therapeutics Inc., BioCell Innovations, bluebird bio, Inc., Bristol-Myers Squibb Company, Caribou Biosciences, Inc., Celyad Oncology SA, CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics, Inc., Genentech, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Miltenyi Biomedicine GmbH, Novartis AG, Sana Biotechnology, Inc., Sangamo Therapeutics, Inc., and Sarepta Therapeutics, Inc. Actionable Recommendations for Industry Leaders to Drive Market Growth

For decision-makers and executives operating within the personalized therapies market, adopting a proactive and adaptive strategy is pivotal to navigating the complex landscape. It is imperative to leverage detailed segmentation analyses to identify underserved patient groups and emerging therapeutic areas. By aligning R&D initiatives with these specific market segments, industry leaders can ensure that their portfolios are both innovative and responsive to real-world clinical needs.

A collaborative approach is equally critical. Strategic partnerships between biopharmaceutical companies, research institutions, and healthcare providers can accelerate the translation of laboratory breakthroughs into clinically effective solutions. Investing in joint ventures and co-development projects paves the way for shared resources and mutual learning, thereby reducing the risk and speeding up time-to-market for new therapies.

Industry players should also focus on expanding their geographic footprint by tailoring market entry strategies to the specific regulatory and cultural landscapes of different regions. Emphasizing the synergistic opportunities present in high-investment regions such as those in the Americas, as well as emerging markets in Europe, the Middle East, Africa, and Asia-Pacific, will play a pivotal role in driving sustained growth.

Moreover, integrating advanced analytics and real-world evidence into decision-making processes can refine forecasting models and enhance patient selection criteria. Utilizing data-driven insights not only optimizes clinical trial designs but also improves overall therapeutic outcomes by ensuring that treatments meet the precise needs of diverse patient groups.

Finally, establishing a robust commercial strategy that includes dynamic pricing models, comprehensive patient education programs, and proactive engagement with regulatory authorities can provide a competitive edge. By continuously monitoring market trends and investing in long-term innovation, leaders can mitigate uncertainty and capitalize on emerging opportunities within this rapidly evolving domain.

Conclusion: Shaping the Future of Personalized Cellular and Genetic Therapies

The journey through the evolving landscape of personalized cell and gene therapies reveals a sector on the cusp of unprecedented transformation. With advancements in biotechnology, innovative research practices, and strategic collaborations, personalized therapies are paving the way towards more effective, targeted treatments that can dramatically improve patient outcomes. The convergence of technological breakthroughs with market-driven insights, detailed segmentation analysis, and regional trends highlights a vibrant ecosystem that is both dynamic and forward-thinking.

As industry leaders navigate this complex terrain, the importance of adaptability and collaboration cannot be overstated. Companies are steadily moving towards embracing integrated approaches that combine state-of-the-art research, patient-centric strategies, and robust manufacturing processes. This multi-dimensional strategy not only aids in addressing current clinical challenges but also sets a foundation for future innovation in treating a diverse array of diseases.

The convergence of strategic partnerships, regulatory support, and ever-evolving technological landscapes ensures that the field remains dynamic, equipped to meet both present and future challenges. In summing up, personalized cell and gene therapies are not merely an incremental improvement over traditional treatment paradigms; they represent a fundamental shift in how diseases are understood and treated, with implications that extend well beyond the laboratory. The insights garnered from this comprehensive analysis provide industry stakeholders with the tools needed to harness the full potential of these transformative therapies as they collectively shape the future of medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing investments and funding in research and development of personalized cell and gene therapies
      • 5.1.1.2. Increasing prevalence of genetic disorders and chronic diseases globally
    • 5.1.2. Restraints
      • 5.1.2.1. Complex and specialized manufacturing processes associated with personalized cell & gene therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development and integration of AI-driven platforms to enhance cell and gene therapy personalization
      • 5.1.3.2. Strategic collaborations between pharma and biotech companies to enhance personalized therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled professionals in personalized cell and gene therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Patient Type: Growing prevalence of spinal muscular atrophy among pediatric patients boosts demand for advanced cell gene therapies
    • 5.2.2. End User: Biopharmaceutical companies focusing on advancing next-generation therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Personalized Cell & Gene Therapies Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy

7. Personalized Cell & Gene Therapies Market, by Patient Type

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Geriatric
  • 7.4. Pediatric

8. Personalized Cell & Gene Therapies Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Hematology
  • 8.4. Immunology
  • 8.5. Metabolic Diseases
  • 8.6. Neurology
  • 8.7. Oncology
  • 8.8. Rare Diseases

9. Personalized Cell & Gene Therapies Market, by End User

  • 9.1. Introduction
  • 9.2. Biopharmaceutical Companies
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutions

10. Americas Personalized Cell & Gene Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Personalized Cell & Gene Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Personalized Cell & Gene Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. NIH's precision medicine trial seeks to revolutionize treatment for myeloid cancers with genetic targeting advancements
    • 13.3.2. Aspen Neuroscience expands San Diego manufacturing hub to accelerate personalized cell therapies for Parkinson's Disease treatment
    • 13.3.3. FDA Approval of Breyanzi as First CAR T Cell Therapy Signals Advancement for Relapsed CLL and SLL
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Limited
  • 2. Allogene Therapeutics
  • 3. Amgen Inc.
  • 4. Arcellx, Inc.
  • 5. Beam Therapeutics Inc.
  • 6. BioCell Innovations
  • 7. bluebird bio, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. Caribou Biosciences, Inc.
  • 10. Celyad Oncology SA
  • 11. CRISPR Therapeutics AG
  • 12. Editas Medicine, Inc.
  • 13. Fate Therapeutics, Inc.
  • 14. Genentech, Inc.
  • 15. Gilead Sciences, Inc.
  • 16. Intellia Therapeutics, Inc.
  • 17. Lonza Group Ltd.
  • 18. Miltenyi Biomedicine GmbH
  • 19. Novartis AG
  • 20. Sana Biotechnology, Inc.
  • 21. Sangamo Therapeutics, Inc.
  • 22. Sarepta Therapeutics, Inc

LIST OF FIGURES

  • FIGURE 1. PERSONALIZED CELL & GENE THERAPIES MARKET MULTI-CURRENCY
  • FIGURE 2. PERSONALIZED CELL & GENE THERAPIES MARKET MULTI-LANGUAGE
  • FIGURE 3. PERSONALIZED CELL & GENE THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 4. PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. PERSONALIZED CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. PERSONALIZED CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERSONALIZED CELL & GENE THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PERSONALIZED CELL & GENE THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PERSONALIZED CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. PERSONALIZED CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 195. PERSONALIZED CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024